FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years
On April 23, 2024, the Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications USA, Inc., a Novartis compan
On April 23, 2024, the Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications USA, Inc., a Novartis compan
Welcome to Childhood Cancer Clinical Data Commons. A primary source for deidentified, individual-level harmonized data that describes the demographic and phenotypic characteristics of participants.
Click to share this newsletter with your colleagues! We hope to see many of you at the 2024 ASCO Annual Meeting in Chicago! FDA Oncology…
Uterine Cancer statistics
Vikram M. Narayan, MD, highlights takeaways from 5-year follow-up data examining the gene therapy nadofaragene firadenovec and details promising emerging therapies for bladder cancer.
Researcher Kenneth Hu, Ph.D., runs an immunology lab studying cell-to-cell interactions in the tumor microenvironment and how that dictates the body’s response to immunotherapy. Here,…
During a Case-Based Roundtable® event, Sumanta K. Pal, MD, moderated a discussion on quality of life data and experiences with dose discontinuation of frontline combination therapy…
Silke Gillessen joins Brian and Tom to give a preview of this year’s ASCO annual meeting, including presentations to look out for on the prostate,…
Vyaire Medical recalls Twin Tube due to potential nozzle separation risk posing a choking hazard.
ASTRO President-elect Sameer Keole, MD, FASTRO, encourages members to think of how they can volunteer for the field by serving on an ASTRO committee or…